RITUXAN SC
As listed in the register: RITUXAN SC
1600 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Rituximab
- Made by
- Hoffmann-La Roche Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Rituxan). It describes the substance, not this exact product.
Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes.
Upon binding to CD20, rituximab mediates B-cell lysis.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-01-06
Safety of the active substance
From the US prescribing label for the same active substance (Rituxan). It describes the substance, not this exact product.
WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning.
The most common adverse reactions of RITUXAN (incidence greater than or equal to 25%) observed in clinical trials of patients with NHL were infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Hoffmann-La Roche Limited |
|---|---|
| Active substance | Rituximab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 1600 mg |
| Form | solution |
| Classification | L01FA01 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02473976 |
| DPD drug code | 96398 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution2 products
- 1400 mg
- 1600 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.